

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
CSO-0001-P

In Re Application Of: Sophie Chen

Serial No.  
10/647,458

Filing Date  
8/1/2003

Examiner

Group Art Unit

Title: **BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
CSO-0001-P

In Re Application: Sophie Chen

Serial No.

10/647,458

Filing Date

8/1/2003

Examiner

Group Art Unit

**BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:


\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 11/03/2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature of Person Mailing Correspondence

Rebecca L. Blake

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate


\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: November 3, 2003

Karen A. LeCuyer  
Registration No. 51,928  
Customer No. 23413  
Cantor Colburn LLP  
55 Griffin Road South  
Bloomfield, CT 06002  
860-286-2929

CC:

<div style="text-align: center;">  <b>INFORMATION DISCLOSURE CITATION</b>          (Use several sheets if necessary)       </div>	ATTY DOCKET NO. <b>CSO-0001-P</b>	SERIAL NO. <b>10/647,458</b>
	Sophie Chen	
	FILING <b>8/1/2003</b>	GROUP


U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	3,472,931	10/14/1969	R. B. Stoughton				
	3,891,757	6/24/1975	Higuchi				
	5,665,393	9/9/1997	Chen et al.				
	5,681,815	10/28/1997	Fan et al.				
	US 2001/0026813 A1	10/4/2001	Kim et al.				
	5,643,598	7/1/1997	Meybeck				
	5,466,452	11/14/1995	Whittle				
	6,162,459	12/19/2000	Hu				

FOREIGN PATENT DOCUMENTS								
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
					YES	NO		
EP 0 257 887 A3	07.08.87	European					✓	
GB 1 001 949	7/19/1962	Great Britain					✓	
GB 1 464 975	3/08/1974	Great Britain					✓	
GB 1 476 016	7/31/1975	Great Britain					✓	
WO 01/51482 A1	19.07.2001	PCT					✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
			Japanese Abstract JP5105613
			Chemical Abstract JP 2000191544

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<div style="text-align: center;">  <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i> </div>	ATTY DOCKET NO. <b>CSO-0001-P</b>	SERIAL NO. <b>10/647,458</b>
	Sophie Chen	
	FILING <b>8/1/2003</b>	GROUP

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 2001/0044431 A1	11/22/2001	Rodriguez			
	US 2003/0035851 A1	2/20/2003	Chen			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/66803 A1	13.09.2001	PCT				✓

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<div style="text-align: center;"> <b>INFORMATION DISCLOSURE CITATION</b>  <i>(Use several sheets if necessary)</i> </div>		Docket Number (Optional) <b>CSO-0001-P</b>	Application Number <b>10/647,458</b>
		Applicant(s) <b>Sophie Chen</b>	
		Filing Date <b>8/1/2003</b>	Group Art Unit
<div style="display: flex; justify-content: space-between;"> <div> <div style="border: 1px solid black; border-radius: 50%; padding: 5px; text-align: center;"> OIP NOV 06 2003 FEDERAL BUREAU OF INVESTIGATION U.S. DEPARTMENT OF JUSTICE </div> <div> *EXAMINER INITIAL &amp; TRADEMARK </div> </div> <div> <b>OTHER DOCUMENTS</b>    <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i> </div> </div>			
Henderson et al., "Hormonal carcinogenesis", Carcinogenesis (2000), 21(3): 427-433			
H. Wiseman, "The therapeutic potential of phytoestrogens", Expert. Opin. Investig. Drugs (2000), 9(8):1829-40			
S. H. Landis et al., "Cancer Statistics, 1998", CA Cancer J. Clin. (1998) 48: 6-29			
National Alliance of Breast Cancer Organizations News, 15(1): 2, January, 2001			
Y. Y. Zhang et al., "Comparative study of Scutellaria planipes and Scutellaria baicalensis"; Biomed. Chromatogra. (1998), 12: 31-3			
H. Hayashi H. et al., "Seasonal variation of glycyrrhizin and isoliquiritgenin glycosides in the root of glycyrrhiza glabra L", Biol. Pharm. Bull. 21(9) 987-989 (1998)			
Yen-Chou <del>Chen</del> et al., "Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide", Biochem. <del>Pharmacology</del> 61 (2001) 1417-1427			
S. Tamir "Estrogen-like activity of glabrene and other constituents isolated from licorice root", J. Steroid Biochem. Mol. Biol. (2001), 78(3): 291-8			
A. Kirschenbaum et al., "The role of cyclooxygenase-2 in prostate cancer" Urology (2001), 58(2 suppl. 1): 127-131			
E. T. Hawk et al., "COX-2 in Cancer-A Player That's Defining the Rules" J. Natl. Cancer Inst. (2002), 94(8): 545-546			
E. Fosslie "Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis", Ann. Clin. Lab. Sci. (2001), 31(4): 325-348			
P. Rivaille et al., C. R. Acad. Sci., Paris, Ser. C (1969), 268(2): 2213-16			
EXAMINER		DATE CONSIDERED	
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

CSO-0001-P

Application Number

10/647,458

Applicant(s)

Sophie Chen

Filing Date

8/1/2003

Group Art Unit

\*EXAMINER

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M. -C. Lin et al., "Supercritical fluid extraction of flavonoids from Scutellariae Radix", J. Chromatogr, A (1999), 830(2): 387-395

S. K. Srivastava et al., Indian J. Chem., Sect. B (1981), 20B(4): 347-8  
*"4,4'-Dihydroxychalcone-2'-O-(4-O-β-D-glucopyranosyl)-α-L-rhamnopyranoside from Viburnum coffretifolium"*

F. A. Macias et al., "Bioactive phenolics and polar compounds from Melilotus messanensis" Phytochemistry (1998), 50(1): 35-46

P. M. Dewick et al., "A Possible Chemical Analogy for Coumestan Biosynthesis", J. Chem. Soc. D (1969), 9: 466-7

T. Kappe et al., "A Simple Synthesis of Coumestrol", Z. Naturforsch., Teil B (1974), 29(3-4): 292-3

R. Laschober et al., "A New and Efficient Synthesis of Coumestan and Coumestrol", Synthesis (1990), 5: 387-8

K. Hiroya et al., "Total syntheses of three natural products, vignafuran, 2-(4-hydroxy-2-methoxyphenyl)-6-methoxybenzofuran-3-carboxylic acid methyl ester, and coumestrol from a common starting material", Perkin 1 (2000), 24: 4339-4346

G. A. Kraus et al., "Hydrogen-Atom Abstraction/Cyclization in Synthesis. Direct Syntheses of Coumestan and Coumestrol", Journal of Organic Chemistry (2000), 65(18): 5644-5646

Chansakraw et al., "Isoflavonoids from Pueraria mirifica and their Estrogenic Activity", Planta Med. (2000), 66(6): 572-575

Halicka et al. "Apoptosis and Cell Cycle Effects Induced by Extracts of the Chinese Herbal Preparation of PC SPES", International J. of Oncology (1997), 11: 437-448


Kyungsil Yoon et al, "Differential activation of wild-type and variant forms of estrogen receptor a by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements", J. Steroid Biochem. & Molecular Biology (2000), 28: pages 25-32


Tzukerman et al. "Human estrogen receptor transactivational capacity is determined by both cellular and promoter content and mediated by two functionally distinct intermolecular regions", Mol. Endocrinol. (1994), 8: 21-30

EXAMINER


DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Docket Number (Optional) <b>CSO-0001-P</b>	Application Number <b>10/647,458</b>
		Applicant(s) <b>S phie Chen</b>	
		Filing Date <b>8/1/2003</b>	Group Art Unit
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)			
		W. Xie, J. G. Chipman, D. L. Robertson, et al., "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing", Proc. Natl. Acad. Sci. USA (1991), 88: 2692-2696	
		K.M. Maxey, K.R. Maddipati, and J. Birkmeier, "Interference in enzyme immunoassays", J. Clin. Immunoassay (1992), 15: 116-120	
		P. Pradelles, J. Grassi, and J. A. Maclouf, "Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay", Anal. Chem. (1985), 57: 1170-1173	
		Maclouf, J., Grassi, J., and Pradelles, P. Development of enzyme-immunoassay techniques for the measurement of eicosanoids, Prostaglandin and Lipid Metabolism in Radiation Injury (1987), pages 355-364	
		Milligan et al., "The endocrine activities of 8-prenylnaringen and related hop (Humulus lupulus L.) flavonoids", The Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 12, pages 4912-4915 (2000).	
		D. R. Budman et al., "Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro", Anticancer Drugs, Vol. 13, No. 10, pages 1011-1016 (2002).	
		M. DiStefano et al., "Antagonistic effect of the combination of gemcitabine/topotecan in ovarian cancer cells," Oncology Research, Vol. 12, No. 9-10, pages 355-359 (2000).	
		Derwent Abstract for JP57167938	
		Derwent Abstract for GB1476016	
		Derwent Abstract for JP52145509	
		Derwent Abstract for JP11236334	
		Derwent Abstract for JP52102434	
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

 <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Docket Number (Optional) <b>CSO-0001-P</b>	Application Number <b>10/647,458</b>
		Applicant(s) <b>S phie Chen</b>	
		Filing Date <b>8/1/2003</b>	Group Art Unit
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)			
		J. Lewis, Jr. and E. R. Berger, New Guidelines for Surviving Prostate Cancer, Health Education Literary Publisher, Westbury, NY (1997), Chapter 17, pages 227-242	
		Kee Chang Huang, editor, The Pharmacology of Chinese Herbs, CRC Press, Inc., 1993, page 352	
		Jiangsu New Medical College, editor; Chinese Medicine Dictionary, Shanghai Science and Technology Press, Shanghai, 1979 Volume 2, pp. 2105-2106	
		M. Tagashira, M. Watanabe, and N. Uemitsu, "Antioxidative Activity of Hop Bitter Acids and Their Analogues", Biosci. Biotechnol. Biochem., Vol. 59, No. 4, pages 740-742 (1995)	
		K. Yuan, R. Hu, C. Ji, and M. Yin, "New Method for Preparing Oridonin by Column Chromatography", Chung Kuo Chung Yao Tsa Chih, Vol. 22, No. 8, pages 478-480, 511 (1997)	
		C. H. Shiao, "Chinese Herbal Medicinal Chemistry", Shanghai Science and Technology Press, 1974, pp. 215	
		T. Hsieh, S. Chen, X. Wang, and J. Wu, "Regulation of Androgen Receptor (AR) and Prostate Specific Antigen (PSA) in the Androgen-Responsive Human Prostate LNCap Cells by Ethanolic Extracts of the Chinese Herbal Preparation PC-SPES." Biochem. Mol. Biol. Int., Vol. 42, pages 535-544 (1997)	
		S. Chen, Q. Ruan, E. Bedner, A. Beptala, X. Wang, T. C. Hsieh, F. Traganos, and Z. Darzynkiewicz, "Effects of the Flavonoid Baicalin and its Metabolite Baicalein on Androgen Receptor Expression, Cell Cycle Progression and Apoptosis of Prostate Cancer Cell Lines", Cell Proliferation, 2001, 34: 293-304	
		Yu Wang, Jun; Xu Xia; G. Shiwen; Zhang, Tanmu; Department of Pharmacology, Henan Institute of Medical Sciences, Zhengzhou, Peoples Rep. China, "Protective effects of diterpenoid compounds on liver mitochondria injury induced by free radicals", Zhongguo Yaolixue Tongbao (199 Zhang), 15(1), 46-48	
		Kadota, Shigetoshi; Basnet, Purusotam; Ishii, Eiji; Tamura Toshihide; Namba Tsuneo. Research Inst. Wakan-Yaku, Toyama Medical Pharmaceutical Univ., Toyama, Japan, "Antibacterial activity of trichorabdol A from Rabdosia trichocarpa against Helicobacter pylori", Zentralbl. Bakteriell, (1997), 286(1), 63-67	
		Wang MY, Lin C, Shang TM, "Effects of oridonin on DNA, RNA and protein synthesis of leukemia L 1210 cells studied by autoradiography", Chung Kuo Yao Li Hsueh Pao, 1987 Mar; 8(2); 164-5	
		Li, Qi; Chen, Yhen; Dept. Pharmacology, Norman Bethune Univ. Medical Science, Changchun, P.R. China, "Effect of oridonin on binding capacity of B-adrenergic receptor and activity of adenylate cyclase", Baiqiuen Yike Daxue Xuebao (1991), 17(2), 152-5	
EXAMINER		DATE CONSIDERED	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



 <b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>CSO-0001-P</b>	Application Number <b>10/647,458</b>
		Applicant(s) <b>Sophie Chen</b>	
		Filing Date <b>8/1/2003</b>	Group Art Unit
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
		Fuji, Kaoru; Node, Manabu; Sai, Midori; Fujita, Elichi; Takeda, Satsuo; Unemi, Norio; Inst. Chem. Res., Kyoto Univ., Kyoto, Japan, "Terpenoids, L111. Antitumor activity of trichorabdals and related compounds", Chem. Pharm. Bull. (1989), 37(6), 1472-6	
		Fujita, Tetsuro; takeda, Yoshio; Sun, Handong; Minami, Yoshinori; Tokushima, Japan, "Cytotoxic and antitumor activities of Radbosia diterpenoids", Planta Med. (1988), 54(5), 414-417	
		Stojakowska et al., "Flavonoid Production in Transformed Root Cultures of Scutellaria baicalensis", J. Plant Physiol. Vol. 156. pp. 121-125 (2000)	
		Yang et al., "Estimation of the Antioxidant Activities of Flavonoids from Their Oxidation Potentials", Analytical Sciences, May 2001, Vol. 17 (2001) 599-604	
		Sophie Chen, "In Vitro Mechanism of PC SPES", Urology (2001) 58(Supplement 2A): 28-35	
		William K. Oh et al., "Activity of the Herbal Combination, PC-SPES, in the Treatment of Patients with Adrogen-Independent Prostate Cancer, Urology (2001) 57(1): 122-126	
		Hank Porterfield, "UsToo PC-SPES Surveys: Review of Studies and Update of Previous Survey Results", Molecular Urology, Volume 4, Number 3, 2000, pp. 289-291	
		B. L. Pfeifer et al., "PC-SPES, a dietary supplement for the treatment of hormone refractory prostate cancer", BJU International (2000), 85, 481-485	
		Eric J. Small et al., "Prospective Trial of the Herbal Supplement PC-SPES in Patients with Progressive Prostate Cancer", Journal of Clinical Oncology, Vol. 18, No 21 (November 1), 2000: pp. 3595-3603	
		Chemical Abstract for CN1268512	
		Roh, Jong Hwa et al. "Phytochemical constituents from Melampyrum roseum var. hirsutum Beauv. Saengyak Hakhoechi (2000), 31(2), 157-162 (Abstract Only)	
		Chansakaow, Sunee et al., "Rejuvenating principles of Pueraria mirifica" of Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (2000), 42nd, 49-54 (Abstract Only)	
EXAMINER		DATE CONSIDERED	
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			